Literature DB >> 2369792

Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II).

M Dumas1, C de Gislain, P d'Athis, V Chadoint-Noudeau, A Escousse, J Guerrin, N Autissier.   

Abstract

It has been reported that hypertonic saline provides protection against the renal toxicity of cisplatin (CDDP). We therefore evaluated its influence on the plasma and urinary pharmacokinetics of ultrafilterable platinum and kidney function as estimated by creatinine, inulin and PAH clearance. We undertook a randomized trial including two groups of ten patients receiving 100 mg/m2 CDDP in isotonic (group 1) or hypertonic saline (group 2) by a 20-min infusion. The hydration consisted of dextrose in group 1 and isotonic saline in group 2. Maximal concentration (Cmax), protein binding and cumulative urinary excretion were significantly higher in the dextrose group. Urinary flow decreased in this group but not in the other one. Inulin clearance was higher in the dextrose group than in the saline group and P-aminohippuric acid (PAH) clearance was not significantly different in these groups of patients. Hyponatremia was observed in the dextrose group. These results suggest that hypertonic saline infusion and saline hydration may enhance the diffusion of CDDP into tissues, lowering Cmax and renal excretion of platinum. The reduction of protein binding may indicate a diminution of aquation of CDDP in plasma. Our results suggest that the infusion of CDDP in hypertonic saline with salt hydration could exert a protective effect on the kidney. Moreover, there is a lessening of the risk of cellular hyperhydration. However, the better influence of dextrose hydration on glomerular filtration leads us to recommend a combination of the two methods of hydration for better tolerance and efficacy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2369792     DOI: 10.1007/bf02897230

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  25 in total

1.  A new method for the determination of inulin in plasma and urine.

Authors:  A HEYROVSKY
Journal:  Clin Chim Acta       Date:  1956 Sep-Oct       Impact factor: 3.786

2.  [Not Available].

Authors:  J HAMBURGER
Journal:  Ann Biol Clin (Paris)       Date:  1948 Jul-Aug       Impact factor: 0.459

3.  Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum.

Authors:  M Dumas; C de Gislain; P d'Athis; V Chadoint-Noudeau; A Escousse; J Guerrin; N Autissier
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Alterations in the toxicity of cis-dichlorodiammineplatinum-II and in tissue localization of platinum as a function of NaCl concentration in the vehicle of administration.

Authors:  C L Litterst
Journal:  Toxicol Appl Pharmacol       Date:  1981-10       Impact factor: 4.219

5.  Stability of cisplatin in aqueous solution.

Authors:  R F Greene; D C Chatterji; P K Hiranaka; J F Gallelli
Journal:  Am J Hosp Pharm       Date:  1979-01

6.  Reduced renal blood flow in early cisplatin-induced acute renal failure in the rat.

Authors:  J A Winston; R Safirstein
Journal:  Am J Physiol       Date:  1985-10

7.  A study of the protective effect of chloride salts on cisplatin nephrotoxicity.

Authors:  P T Daley-Yates; D C McBrien
Journal:  Biochem Pharmacol       Date:  1985-07-01       Impact factor: 5.858

8.  Disposition of unchanged cisplatin in patients with ovarian cancer.

Authors:  P A Reece; I Stafford; M Davy; S Freeman
Journal:  Clin Pharmacol Ther       Date:  1987-09       Impact factor: 6.875

9.  Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II).

Authors:  R J Belt; K J Himmelstein; T F Patton; S J Bannister; L A Sternson; A J Repta
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

10.  Clinical pharmacology of high-dose cisplatin.

Authors:  B J Corden; R L Fine; R F Ozols; J M Collins
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

View more
  6 in total

Review 1.  Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review.

Authors:  V Pinzani; F Bressolle; I J Haug; M Galtier; J P Blayac; P Balmès
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits.

Authors:  R Kizu; S Higashi; Y Kidani; M Miyazaki
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.

Authors:  W P Petros; S G Chaney; D C Smith; J Fangmeier; M Sakata; T D Brown; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies.

Authors:  Gino In; Tanya Dorff
Journal:  Urol Clin North Am       Date:  2015-08       Impact factor: 2.766

Review 5.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

6.  Renal salt wasting in patients treated with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small cell lung cancer.

Authors:  Y K Lee; D M Shin
Journal:  Korean J Intern Med       Date:  1992-07       Impact factor: 2.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.